HumanHap BeadChips are powered by the Company's revolutionary Infinium(TM) assay method (see Note), which enables Illumina to select SNPs that have the highest per-marker information value, resulting in comprehensive genomic coverage with fewer SNP markers than competing approaches. Each of the new HumanHap550 BeadChips will contain roughly 555,000 markers derived principally from so-called "tagSNPs" identified and validated in both phases of the International HapMap Project, which was completed in October 2005.
TagSNPs deliver high information value to geneticists because they serve as "proxies" for larger groups of SNPs, called haplotypes, which are inherited together. Researchers can analyze human populations comprehensively and efficiently by examining between 250,000 and 500,000 tagSNPs instead of the entire set of roughly 10 million SNPs -- opening doors to genome-wide disease association studies now in progress. Sentrix HumanHap BeadChips are the only whole-genome genotyping arrays with tagSNP-centric content.
In addition to comprehensive genomic coverage, HumanHap BeadChips offers the highest data quality of any genotyping array currently available, with call rates that routinely exceed 99%, reproducibility and accuracy approaching 100%. Market uptake of Illumina's HumanHap BeadChips has been strong, and Illumina's whole-genome genotyping solutions have become important discovery tools for researchers seeking to understand the genetic basis of common, yet complex diseases.
The new Sentrix HumanHap BeadChips are part of Illumina's growing genotyping portfolio that includes whole-genome arrays, focused-content arrays and SNP panels, and powerful assay protocols such as the GoldenGate(R) and Infinium assays. Illumina also works with customers to install robust infrastructure solutions, including automation and LIMS (laboratory information management systems) for large-scale sample throughput, positive sample tracking, and data analysis and management.
"The development of the HumanHap550 leveraged the infrastructure that we built as part of our 100K and 300K programs allowing us to quickly bring to market a BeadChip with the industry's highest genomic coverage for whole-genome genotyping," stated Jay Flatley, Illumina President and CEO. "We believe that the launch of the HumanHap550 will further fuel the explosive growth of this market," Flatley concluded.
For more information about the new HumanHap BeadChips, contact Illumina's Customer Solutions organization at +1 858-202-4566 or e-mail email@example.com.
Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, the Company's ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix(R) arrays -- including HumanHap BeadChips -- and Oligator(R) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.
Infinium Assay Note
The Infinium Assay is notable for its simplicity, its high locus specificity and allelic discrimination, and its ability to interrogate a broad range of SNPs with little constraint on locus selection. This, in turn, enables scalability limited only by the number of features on the array itself (the HumanHap550 BeadChip contains over 12 million features). Following single-tube, whole-genome amplification (no PCR or ligation steps), samples are hybridized to 50-mer bead-based probes. After a labeled extension step, the BeadChip is imaged on Illumina's BeadArray Reader, and then analyzed.
Additional Assay Reference
Whole-Genome Genotyping with the Single-Base Extension Assay, Frank J. Steemers, Weihua Chang, Grace Lee, David Barker, Richard Shen and Kevin Gunderson, Nature Methods, Vol. 3, No. 1, January 2006.